The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction
From the European Journal of Heart Failure Study design paper: "Benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF) have not been established. Conventional randomized controlled trials are complex and expensive. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF) is a unique pragmatic registry-based randomized controlled trial."
Acronym: SPIRRIT-HFpEF
Clinical Centers: 78
Participants: 2,400
Beginning:
Ending:
Funding: The Swedish Heart-Lung Foundation, The Swedish Research Council, The Erling Persson Foundation, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), National Institutes of Health Center for Advancing Translational Science (NCATS)
Study Design: Interventional